OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm's stock in a transaction dated Thursday, September 15th. The shares were bought at an average cost of $2.06 per share, with a total value of $412,000.00. Following the purchase, the chief executive officer now directly owns 197,456,694 shares of the company's stock, valued at approximately $406,760,789.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Phillip Md Et Al Frost also recently made the following trade(s):
Get OPKO Health alerts:- On Wednesday, August 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.54 per share, for a total transaction of $508,000.00.
- On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $801,500.00.
- On Tuesday, June 21st, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.39 per share, for a total transaction of $478,000.00.
OPKO Health Price Performance
NASDAQ OPK opened at $2.05 on Monday. The firm's fifty day simple moving average is $2.42 and its two-hundred day simple moving average is $2.81. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. OPKO Health, Inc. has a 12-month low of $1.96 and a 12-month high of $5.25. The firm has a market capitalization of $1.58 billion, a P/E ratio of -7.07 and a beta of 1.75.
OPKO Health (NASDAQ:OPK – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). OPKO Health had a negative return on equity of 7.72% and a negative net margin of 14.18%. The firm had revenue of $309.90 million during the quarter, compared to analysts' expectations of $326.87 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. OPKO Health's revenue for the quarter was down 30.0% compared to the same quarter last year. Analysts forecast that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.Wall Street Analyst Weigh In
Separately, Piper Sandler cut their price objective on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Friday, August 5th.
Hedge Funds Weigh In On OPKO Health
Institutional investors and hedge funds have recently bought and sold shares of the company. Verition Fund Management LLC purchased a new stake in shares of OPKO Health during the second quarter valued at $36,000. Centiva Capital LP purchased a new stake in shares of OPKO Health during the second quarter valued at $131,000. Captrust Financial Advisors grew its holdings in shares of OPKO Health by 13.3% during the second quarter. Captrust Financial Advisors now owns 38,847 shares of the biotechnology company's stock valued at $98,000 after buying an additional 4,573 shares during the last quarter. Creative Planning grew its holdings in shares of OPKO Health by 4.6% during the second quarter. Creative Planning now owns 89,210 shares of the biotechnology company's stock valued at $226,000 after buying an additional 3,963 shares during the last quarter. Finally, Occudo Quantitative Strategies LP grew its holdings in shares of OPKO Health by 143.7% during the second quarter. Occudo Quantitative Strategies LP now owns 75,403 shares of the biotechnology company's stock valued at $191,000 after buying an additional 44,460 shares during the last quarter. 27.83% of the stock is owned by hedge funds and other institutional investors.
About OPKO Health
(Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
See Also
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.